5 completed, 3 terminated, 3 unknown, 1 active not recruiting. 12 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 5, Terminated 3, Unknown 3, Active not recruiting 1 |
| Phase 1 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Acute-graft-versus-host Disease: new trials by email Literature Review of Acute-graft-versus-host Disease trials Research Report on Acute-graft-versus-host Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ASC930 in Patients With Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD) ASC930 - Acute-graft-versus-host Disease | Phase 2 | Unknown | ASC Therapeutics | 60 | 2023-12-01 | 2023-07-20 |
| Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids - Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Terminated | Masonic Cancer Center, University of Minnesota | 10 | 2023-06-05 | 2026-03-24 |
| Abatacept s.c. for aGVHD Prevention in Haplo-HCT Abatacept s.c. - Abatacept, Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 29 | 2021-06-01 | 2026-06-11 |
| Extracorporal Photopheresis With UVADEX Plus Standard Steroid Treatment for High Risk Acute Graft-versus-host Disease Uvadex - Acute-graft-versus-host Disease | Phase 2 | Active not recruiting | Universitätsklinikum Hamburg-Eppendorf | 24 | 2020-05-18 | 2025-03-30 |
| RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation RGI-2001, Standard of Care - Graft Vs Host Disease, Graft-versus-host-disease | Phase 2 | Completed | Regimmune Corporation | 49 | 2019-11-25 | 2024-05-28 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD EQ001, EQ001 Placebo - Acute-graft-versus-host Disease, aGVHD | Phase 1 / Phase 2 | Completed | Biocon Limited | 30 | 2019-07-15 | 2026-06-11 |
| The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant AAT, Placebo - Acute-graft-versus-host Disease | Phase 2 / Phase 3 | Terminated | CSL Behring | 222 | 2019-03-27 | 2026-09-09 |
| UCMSCs as Front-line Approach of Treatment for Patients With aGVHD Umbilical cord derived mesenchymal stem cell, Placebo - Acute-graft-versus-host Disease | Phase 1 / Phase 2 | Completed | Cytopeutics Sdn. Bhd. | 26 | 2019-02-01 | 2026-01-02 |
| A Study Comparing Corticosteroids Alone Versus Corticosteroids and Extracorporal Photopheresis (ECP) as First-line Treatment of Standard II Acute Graft-versus-host Disease Methoxsalen + ECP device, Corticosteroids - Acute-graft-versus-host Disease | Phase 2 | Unknown | Central Hospital, Nancy, France | 78 | 2018-10-01 | 2018-07-30 |
| An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD) Defibrotide, Standard of Care - Graft-versus-host Disease, Acute-graft-versus-host Disease | Phase 2 | Completed | Jazz Pharmaceuticals | 152 | 2018-02-21 | 2021-08-18 |
| Cannabidiol for the Treatment of Severe (Grades III/IV) Acute Graft-versus-host Disease Cannabidiol, Methylprednisolone, Calcineurin inhibitor - Acute-graft-versus-host Disease | Phase 2 | Unknown | moshe yeshurun | 10 | 2015-04-01 | 2015-03-19 |
| Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT Sirolimus, Mycophenolate mofetil (MMF), Carmustine - Hematologic Diseases, Acute-graft-versus-host Disease | Phase 2 | Terminated | Stanford University | 3 | 2006-08-01 | 2017-06-05 |
Graft vs Host Disease (3) · Hematologic Diseases (1) · Hodgkin Disease (1) · Leukemia (1) · Lymphoma, Non-Hodgkin (1)
Immune System Diseases (4) · Hemic and Lymphatic Diseases (1) · Immunoproliferative Disorders (1) · Lymphatic Diseases (1) · Lymphoma (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Adrenal Cortex Hormones (2) · Methoxsalen (2) · Methylprednisolone (2) · Standard of Care (2) · Calcineurin Inhibitors (1) · Cannabidiol (1) · Carmustine (1) · Chorionic Gonadotropin (1) · Cyclophosphamide (1) · Etoposide (1) · KRN 7000 (1) · Mycophenolic Acid (1) · Prednisone (1) · Respreeza (1) · Sirolimus (1)
ASC Therapeutics (1) · Biocon Limited (1) · CSL Behring (1) · Central Hospital, Nancy, France (1) · Cytopeutics Sdn. Bhd. (1) · Jazz Pharmaceuticals (1) · Masonic Cancer Center, University of Minnesota (1) · Regimmune Corporation (1) · Stanford University (1) · The First Affiliated Hospital of Soochow University (1) · Universitätsklinikum Hamburg-Eppendorf (1) · moshe yeshurun (1)
United States (6) · Germany (3) · Austria (2) · Italy (2) · Spain (2) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · China (1) · Croatia (1) · France (1) · Greece (1) · Israel (1) · Japan (1)
Francis A. Ayuk, Prof. Dr. (1) · Joel Rothman (1) · Laura Johnston (1) · Sen Mui Tan (1) · Sherman Holtan, MD (1) · Yi-Bin Chen, MD (1)
PMID 35484649, PMID 36519326, PMID 40680268
2017 (1), 2018 (1)